
Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Need Help?
Announcements
21 April 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Gastrointestinal Oncology”
As Current Oncology (ISSN: 1718-7729) is of open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers of the Section “Gastrointestinal Oncology” shown below:
1. “Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29(3), 1559-1574; https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131
2. “Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI”
by Jelena Djokic Kovač, Aleksandra Janković, Aleksandra Đikić-Rom, Nikica Grubor, Andrija Antić and Vladimir Dugalić
Curr. Oncol. 2022, 29(2), 698-723; https://doi.org/10.3390/curroncol29020061
Available online: https://www.mdpi.com/1718-7729/29/2/61
3. “Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma”
by Tadahisa Inoue, Itaru Naitoh, Rena Kitano, Mayu Ibusuki, Yuji Kobayashi, Yoshio Sumida, Yukiomi Nakade, Kiyoaki Ito and Masashi Yoneda
Curr. Oncol. 2022, 29(4), 2240-2251; https://doi.org/10.3390/curroncol29040182
Available online: https://www.mdpi.com/1718-7729/29/4/182
4. “A Pleiotropic Role of Long Non-Coding RNAs in the Modulation of Wnt/β-Catenin and PI3K/Akt/mTOR Signaling Pathways in Esophageal Squamous Cell Carcinoma: Implication in Chemotherapeutic Drug Response”
by Uttam Sharma, Masang Murmu, Tushar Singh Barwal, Hardeep Singh Tuli, Manju Jain, Hridayesh Prakash, Tea Kaceli, Aklank Jain and Anupam Bishayee
Curr. Oncol. 2022, 29(4), 2326-2349; https://doi.org/10.3390/curroncol29040189
Available online: https://www.mdpi.com/1718-7729/29/4/189
5. “Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies”
by Miguel A. Ortega, Leonel Pekarek, Oscar Fraile-Martinez, Cielo Garcia-Montero, Miguel A. Saez, Angel Asúnsolo, Miguel A. Alvarez-Mon, Jorge Monserrat, Lidia Ruiz-Llorente, Natalio García-Honduvilla et al.
Curr. Oncol. 2022, 29(4), 2442-2453; https://doi.org/10.3390/curroncol29040198
Available online: https://www.mdpi.com/1718-7729/29/4/198
6. “Immunotherapy in Squamous Cell Cancer of the Esophagus”
by Peter Thuss-Patience and Alexander Stein
Curr. Oncol. 2022, 29(4), 2461-2471; https://doi.org/10.3390/curroncol29040200
Available online: https://www.mdpi.com/1718-7729/29/4/200
7. “Tumor Stroma Ratio and Its Significance in Locally Advanced Colorectal Cancer”
by Luz Sullivan, Richard R. Pacheco, Michel Kmeid, Anne Chen and Hwajeong Lee
Curr. Oncol. 2022, 29(5), 3232-3241; https://doi.org/10.3390/curroncol29050263
Available online: https://www.mdpi.com/1718-7729/29/5/263
8. “Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future”
by Alessandro Rizzo, Angela Dalia Ricci, Antonio Cusmai, Silvana Acquafredda, Giuseppe De Palma, Giovanni Brandi and Gennaro Palmiotti
Curr. Oncol. 2022, 29(2), 551-564; https://doi.org/10.3390/curroncol29020050
Available online: https://www.mdpi.com/1718-7729/29/2/50
9. “An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer”
by Alessandra Anna Prete, Letizia Procaccio, Francesca Bergamo, Cosimo Rasola, Floriana Nappo, Vittorina Zagonel and Sara Lonardi
Curr. Oncol. 2022, 29(2), 544-550; https://doi.org/10.3390/curroncol29020049
Available online: https://www.mdpi.com/1718-7729/29/2/49
10. “In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma”
by Yue Wang, Xulong Huang, Siyu Chen, Huajuan Jiang, Huanan Rao, Lijie Lu, Feiyan Wen and Jin Pei
Curr. Oncol. 2022, 29(9), 6573-6593; https://doi.org/10.3390/curroncol29090517
Available online: https://www.mdpi.com/1718-7729/29/9/517